Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Interventional × birtamimab × Clear all

Phase

Phase 2 3 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cisplatin 634 Carboplatin 527 Paclitaxel 508 Cyclophosphamide 468 Radiotherapy 463 Docetaxel 423 Fluorouracil 402 Gemcitabine 378 Doxorubicin 357 Capecitabine 325 Dexamethasone 289 Oxaliplatin 259 Vincristine 248 Leucovorin 248 Etoposide 245 pembrolizumab 240 Bevacizumab 237 Rituximab 221 Prednisone 207 Pemetrexed 187 Cytarabine 185 Drug Therapy 176 Methotrexate 155 Trastuzumab 154 Irinotecan 149 Lenalidomide 126 Filgrastim 122 Nivolumab 117 Tamoxifen 113 Chemotherapy, Adjuvant 113

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02312206 2023-11-14

VITAL

Prothena Biosciences Ltd.

Phase 3 Terminated

260 enrolled 11 charts

Immunoglobulin Light-chain Amyloidosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡